Pfizer's $43 billion acquisition of Seagen, a biotechnology company specializing in cancer treatments, is aimed at expanding Pfizer's market in oncology. This is a needle-sharp case of problem reaction solution. The exposure of the medical industry is going to be the hardest pill for people of the world to swallow.

Pfizer's $43 billion acquisition of Seagen, a biotechnology company specializing in cancer treatments, is aimed at expanding Pfizer's market in oncology. This is a needle-sharp case of problem reaction solution.